



ELDER PHARMACEUTICALS LTD.

Registered Office: Elder House, C-9, Dalia Industrial Estate, Off New Link Road,
Andheri (West), Mumbai-400 053.

Un-audited Standalone Financial Results (Provisional) For The Quarter Ended 31st March, 2010

(Rs. in Lakhs)

Sr. No.	PARTICULARS	3 months ended 31.03.2010 (Unaudited)	Corresponding 3 months ended in the previous year 31.03.2009 (Unaudited)	Year to date figures for the current period ended 31.03.2010 (Unaudited)	Previous accounting year ended 31.03.2009 (Audited)
1	a) Net sales / Income from operations	18969.44	15758.83	70197.54	61940.48
	b) Other operating income	10.16	14.14	44.70	61.70
	Total Income (a + b)	18979.60	15772.97	70242.24	62002.18
2	Expenditure				
	a) Increase (-) / Decrease (+) in stock in trade and work in process.	-2451.11	-844.48	-5133.95	-568.69
	b) Consumption of Raw Materials	3353.16	3024.38	11616.49	9645.43
	c) Purchase of traded goods	8029.37	4922.67	26650.33	21074.56
	d) Employees cost	2485.24	2446.93	9915.13	8336.74
	e) Depreciation	455.11	366.16	1503.43	1152.33
	f) Other Expenditure	4135.01	3875.20	14257.25	13430.11
	g) Total	16006.78	13790.86	58808.68	53070.48
3	Profit from operations before other income, interest & exceptional items	2972.82	1982.11	11433.56	8931.70
4	Other income	320.69	157.88	802.42	813.84
5	Profit before interest & exceptional items	3293.51	2139.99	12235.98	9745.54
6	Interest	1284.80	983.41	5234.51	3739.34
7	Profit after interest but before exceptional items	2008.71	1156.58	7001.47	6006.20
8	Exceptional items	127.32	0.00	475.61	147.15
9	Profit from ordinary activities before tax	1881.39	1156.58	6525.86	5859.05
10	Tax expenses (Refer note number 6 below)	200.00	150.00	1000.00	794.70
11	Net profit from ordinary activities after tax	1681.39	1006.58	5525.86	5064.35
12	Extraordinary items (Net of tax expenses)	0.00	0.00	0.00	0.00
13	Net profit for the period	1681.39	1006.58	5525.86	5064.35
14	Paid up equity share capital (Face value Rs.10/-)	1885.74	1885.74	1885.74	1885.74
15	Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	39644.26
16	Earnings Per Share (EPS)				
	a) Basic & diluted EPS before extraordinary items for the period, for the year to date & for the previous year	8.92	5.34	29.30	26.86
	b) Basic & diluted EPS after extraordinary items for the period, for the year to date & for the previous year	8.92	5.34	29.30	26.86
17	Public shareholding				
	- Number of shares	11215678	11603212	11215678	11603212
	- Percentage of shareholding	59.47	61.53	59.47	61.53
18	Promoters & Promoter Group Shareholding				
	A) Pledged/Encumbered				
	- Number of Shares	4534279	4287900	4534279	4287900
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	59.34	59.11	59.34	59.11
	- Percentage of shares(as a % of the total share capital of the company)	24.04	22.74	24.04	22.74
	B) Non-Encumbered				
	- Number of Shares	3107529	2966374	3107529	2966374
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	40.66	40.89	40.66	40.89
	- Percentage of shares (as a % of total share capital of the company)	16.48	15.73	16.48	15.73

Notes:

- 1) The above results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 5th May 2010
- 2) The statutory Auditors have carried out a limited review of the unaudited (provisional) financial results for the quarter ended 31st March, 2010
- 3) The Company operate in Pharmaceutical segment only. Hence, pursuant to accounting standard AS-17 on segment reporting, segmental information is not required to be given.